Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lessons from human mutations in PPARgamma.

R A Hegele1

  • 1Robarts Research Institute, London, Ontario, Canada. hegele@robarts.ca

International Journal of Obesity (2005)
|February 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye.

Journal of clinical lipidology·2024
Same author

Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.

Journal of internal medicine·2019
Same author

Conservative management in hypertriglyceridemia-associated pancreatitis.

Journal of internal medicine·2019
Same author

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.

BMC neurology·2019
Same author

Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a).

Journal of thrombosis and haemostasis : JTH·2017
Same author

Atypical Presentation and Treatment Response in a Child with Familial Hypercholesterolemia Having a Novel LDLR Mutation.

JIMD reports·2016

Rare mutations in the PPARgamma gene cause familial partial lipodystrophy (FPLD3), leading to metabolic issues like insulin resistance. These PPARgamma mutations result in less severe fat loss but more pronounced metabolic problems compared to LMNA-related FPLD.

Area of Science:

  • Genetics
  • Endocrinology
  • Metabolic Disorders

Background:

  • Familial partial lipodystrophy (FPLD) involves adipose tissue redistribution and metabolic disturbances.
  • FPLD2 is linked to LMNA mutations, while FPLD3 is associated with germline mutations in PPARgamma.

Purpose of the Study:

  • To investigate the role of PPARgamma mutations in familial partial lipodystrophy.
  • To characterize the clinical and biochemical features of FPLD3 patients with PPARgamma mutations.

Main Methods:

  • Genetic analysis of families with partial lipodystrophy and normal LMNA sequences.
  • Functional studies of mutant PPARgamma receptors to assess transcriptional activity.
  • Clinical and biochemical evaluation of patients with FPLD3.

Related Experiment Videos

Main Results:

  • Identified heterozygous PPARgamma mutations (e.g., F388L) in FPLD3 kindreds.
  • Mutant PPARgamma showed reduced basal activity and impaired response to rosiglitazone.
  • FPLD3 patients exhibited less severe lipodystrophy but more severe insulin resistance compared to FPLD2.

Conclusions:

  • Germline mutations in PPARgamma cause familial partial lipodystrophy (FPLD3).
  • PPARgamma mutations affect ligand binding and transactivation, leading to metabolic syndrome-like features.
  • FPLD3 presents with distinct clinical and biochemical profiles compared to FPLD2.